(17 days)
No
The summary describes standard SPECT/CT imaging technology and software for image display and analysis. There is no mention of AI or ML algorithms being used for image processing, analysis, or any other function. The performance studies and metrics are also standard for this type of imaging device.
No
The device is described as an imaging system used for detecting, localizing, diagnosing, and staging diseases, and for aiding in radiotherapy treatment planning and interventional radiology procedures, not for treating conditions itself.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is intended "to aid in detecting, localizing, diagnosing, staging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders."
No
The device description clearly states the system consists of SPECT scanners and integrated hybrid CT and SPECT scanners, which are hardware components. While the software component is mentioned, it is part of a larger hardware system.
Based on the provided text, the Siemens Symbia series is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD devices are used to examine specimens derived from the human body. The intended use and device description clearly state that the Symbia series is used to image the distribution of radionuclides in the body and produce cross-sectional images of the body. It works by detecting signals from within the patient, not by analyzing samples taken from the patient.
- The device description focuses on imaging modalities (SPECT and CT) and their function in visualizing internal structures and physiological processes. This is characteristic of in vivo diagnostic imaging devices, not in vitro diagnostics.
- The performance studies mentioned relate to imaging performance (quantitative accuracy in phantoms, NEMA standards), not the analysis of biological samples.
In summary, the Siemens Symbia series is an in vivo diagnostic imaging device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Siemens Symbia series is intended for use by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning and interventional radiology procedures.
SPECT: The SPECT component is intended to detect or image the distribution of radionuclides in the body or organ (physiology), using the following techniques; Planar imaging, and tomographic imaging for isotopes with energies up to 588 keV.
CT: The CT component is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data (anatomy) from either the same axial plane taken at different angles or spiral planes take at different angles.
SPECT+CT: The SPECT and CT components used together acquire SPECT/CT images can be corrected for attenuation with the CT images, and can be combined (image registration) to merge the patient's physiological (SPECT) and anatomical (CT) images.
Software: the syngo MI Applications software is a display and analysis package intended to aid the clinician in the assessment and quantification of pathologies in images produced from SPECT, PET, CT and other imaging modalities.
Product codes (comma separated list FDA assigned to the subject device)
KPS, JAK
Device Description
The Siemens Symbia systems consist of Single Photon Emission Computed Tomography (SPECT) scanners and integrated hybrid X-Ray Computed Tomography (CT) and SPECT scanners. The SPECT subsystem images and measures the distribution of radiopharmaceuticals in humans for the purpose of determining various metabolic (molecular) and physiologic functions within the human body and integrates CT's anatomical detail for precise reference of the location of the metabolic activity. The CT component produces cross-sectional images of the body by computer reconstruction of X-Ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles. The system can be used as an integrated SPECT and CT modality while also enabling independent functionality of SPECT and CT as standalone diagnostic imaging devices.
Modifications in Symbia 6.5 include:
- Upgraded software syngo MI Applications VB20A which incorporates expansions of commercially available xSPECT Quantification (Symbia 5.0 K131634)
- Implementation of commercially marketed CT software, (K151752, 'CT SOMARIS/5 VC30')
- Integration of commercially marketed software application syngo TrueD (K101749) for viewing, manipulation, 3D visualization and comparison of medical images from multiple imaging modalities.
- Hardware upgrade; four additional touchpad sensors to cover detectors' light rails and L-arms
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
SPECT, CT, PET
Anatomical Site
Body, Organ
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Appropriately trained health care professionals, physician
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing for the CT subsystem was included in the original premarket notification for the CT subsystems and there have been no changes affecting this testing.
Symbia 6.5 is designed in accordance with the 60601-1 series including all relevant collateral standards general (IEC 60601-1, 1-2, 1-3, etc) and specific (IEC 60601-2-44). Performance testing is conducted according to NEMA NU-1:2012. All Performance testing met the predetermined acceptance values.
Quantitative accuracy of 3/8" and 5/8" phantoms was evaluated.
The quantitative error for all supported isotopes with the collimators is smaller or equal to 10%, and met the predefined acceptance criteria.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Quantitative Accuracy:
3/8" Phantom: Deviation from true (%)
§ 892.1200 Emission computed tomography system.
(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services - USA. The logo features a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized graphic of three human profiles facing to the right, with flowing lines beneath them, creating a sense of movement or connection.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 8, 2016
Siemens Medical Solutions, USA, Inc. % Ms. Cynthia Busch Regulatory Affairs Specialist 2501 N. Barrington Road HOFFMAN ESTATES IL 60192
Re: K162337
Trade/Device Name: Symbia 6.5 Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: II Product Code: KPS, JAK Dated: August 22, 2016 Received: August 23, 2016
Dear Ms. Busch:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041
1
Page 2— Ms. Cynthia Busch
or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Michael D'Hara
For
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name Symbia 6.5
Indications for Use (Describe)
The Siemens Symbia series is intended for use by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning and interventional radiology procedures.
SPECT: The SPECT component is intended to detect or image the distribution of radionuclides in the body or organ (physiology), using the following techniques; Planar imaging, and tomographic imaging for isotopes with energies up to 588 keV.
CT: The CT component is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data (anatomy) from either the same axial plane taken at different angles or spiral planes take at different angles.
SPECT+CT: The SPECT and CT components used together acquire SPECT/CT images can be corrected for attenuation with the CT images, and can be combined (image registration) to merge the patient's physiological (SPECT) and anatomical (CT) images.
Software: the syngo MI Applications software is a display and analysis package intended to aid the clinician in the assessment and quantification of pathologies in images produced from SPECT, PET, CT and other imaging modalities.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------ |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
as required by 21 CFR Part 807.87(h) and 21 CFR Part 807.92(c)
Identification of the Submitter
| Submitter: | Cynthia Busch
Regulatory Technical Specialist
Siemens Medical Solutions USA, Inc.
2501 N. Barrington Road
Hoffman Estates, IL 60192
USA |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Name / Address of Manufacturer: | Siemens Medical Solutions USA, Inc
Molecular Imaging
2501 N. Barrington Road
Hoffman Estates, IL 60192
USA |
| Telephone Number: | (847) 304-7095 |
| Fax Number: | (847) 304-6023 |
| Date of Submission: | August 19, 2016 |
| Identification of the product | |
| Device Proprietary Name: | Symbia 6.5 |
| Common Name: | Single-photon emission computed tomography (SPECT)
system
Computed Tomography (CT) System |
| Classification Name: | Emission Computed Tomography per 21 CFR 892.1200
Computed Tomography X-Ray System per 21 CFR 892.1750 |
| Product Code: | KPS and JAK |
| Classification Panel: | Radiology |
| Class: | II |
4
Marketed Devices to which Equivalence is claimed
Predicate:
| Device Proprietary Name: | Symbia 6.0 |
|---|---|
| Manufacturer: | Siemens Medical Solutions USA, Inc |
| Product Code: | KPS and JAK |
| Device Class: | II |
| 510(k) Number: | K142006 |
| Reference Device(s): | |
| Device Name(s): | CT SOMARIS/5 VC30 |
| 510(k) Number(s): | K151752 |
Device Description:
The Siemens Symbia systems consist of Single Photon Emission Computed Tomography (SPECT) scanners and integrated hybrid X-Ray Computed Tomography (CT) and SPECT scanners. The SPECT subsystem images and measures the distribution of radiopharmaceuticals in humans for the purpose of determining various metabolic (molecular) and physiologic functions within the human body and integrates CT's anatomical detail for precise reference of the location of the metabolic activity. The CT component produces cross-sectional images of the body by computer reconstruction of X-Ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles. The system can be used as an integrated SPECT and CT modality while also enabling independent functionality of SPECT and CT as standalone diagnostic imaging devices.
| Symbia 6.0 Family | ||
|---|---|---|
| SPECT only systems | Symbia E Single | variable angle, single detector gamma camera |
| Symbia E Dual | variable angle, dual detector gamma camera | |
| Symbia S | variable angle dual detector SPECT system | |
| Symbia Evo | variable angle dual detector SPECT system |
All systems implement a new software version syngo MI Applications VB20A.
5
| Symbia Evo Excel | variable angle dual detector SPECT system | |
|---|---|---|
| Symbia T series | a variable angle dual detector SPECT with a | |
| 2, 6, or 16-slice spiral CT | ||
| SPECT/CT Systems | Symbia Intevo Excel | SPECT/CT system with non-diagnostic CT |
| support for only attenuation correction and | ||
| anatomical localization | ||
| Symbia Intevo Series | variable angle dual detector SPECT and 2, 6, | |
| or 16-slice spiral CT to give the system full | ||
| functionality for all SPECT-only, xSPECT, or | ||
| stand-alone CT diagnostic applications |
Modifications in Symbia 6.5 include:
- Upgraded software syngo MI Applications VB20A which incorporates expansions of commercially available xSPECT Quantification (Symbia 5.0 K131634)
- Implementation of commercially marketed CT software, (K151752, 'CT ● SOMARIS/5 VC30')
- Integration of commercially marketed software application syngo TrueD ● (K101749) for viewing, manipulation, 3D visualization and comparison of medical images from multiple imaging modalities.
- . Hardware upgrade; four additional touchpad sensors to cover detectors' light rails and L-arms
Intended Use:
The Symbia Intevo Excel, Intevo series and T series are radiological imaging systems that combine a single photon emission computed tomography (SPECT) camera system for nuclear medicine images, and a computed tomography (CT) camera system for x-ray images. The Symbia E series, Symbia S, Evo, and Evo Excel systems are SPECT camera systems.
The SPECT system is intended to detect the location and distribution of gamma ray radionuclides in the body and produce cross-sectional images through computer reconstruction of the data, and the CT system is intended to produce cross-sectional imaqes of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. The nuclear medicine images and the x-ray images may be reqistered and displayed in a fused format (overlaid in the same orientation) for the anatomical localization of the nuclear medicine data (that is, distribution of radiopharmaceuticals).
The SPECT and CT portions of the system may be used independently or in combination, and may include signal analysis and display equipment, patient and equipment supports,
6
radionuclide anatomical markers, component parts, and accessories. The SPECT and CT imaqes may be transferred to other systems for radiation therapy planning or additional uses.
Indications for Use:
The Siemens Symbia series is intended for use by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging and restaging of lesions, tumors, disease and orqan function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning and interventional radiology procedures.
SPECT: To detect or image the distribution of radionuclides in the body or organ, using the following techniques: planar imaging, whole body imaging, tomographic imaging for isotopes with energies up to 588keV
CT: The CT component is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles.
SPECT+CT: Perform CT scans and nuclear imaging studies with the same instrument. To obtain attenuation corrected images and to provide registration of anatomical and physiological images within the patient's anatomy.
Software: The MI Applications software is a display and analysis package intended to aid the clinician in the assessment and quantification of pathologies taken from SPECT, PET, CT and other imaging modalities.
Technological Characteristics:
Symbia 6.5 systems are based on the commercially available Symbia 6.0 (K142006). The software updates are based on the same fundamental technology of the xSPECT quantification in Symbia SPECT/CT predicate components. SPECT detector, existing collimators, and CT performance specifications do not change between the commercially available Symbia 6.0 systems and Symbia 6.5 systems. The syngo TrueD software application, incorporated into the updated software, is commercially available (K101749).
Performance Testing:
Performance testing for the CT subsystem was included in the original premarket notification for the CT subsystems and there have been no changes affecting this testing.
Symbia 6.5 is designed in accordance with the 60601-1 series including all relevant collateral standards general (IEC 60601-1, 1-2, 1-3, etc) and specific (IEC 60601-2-44). Performance testing is conducted according to NEMA NU-1:2012. All Performance testing met the predetermined acceptance values.
7
Table 1 and 2 depict quantitative accuracy of 3/8" and 5/8"
Acceptance criteria: The absolute quantification accuracy of the system shall be within 10% in phantoms for objects larger than three times the system resolution when acquired for count rates up to 160 kcps.
| 3/8" | Acceptance
Criteria | Deviation
from true
(%) |
|---------|------------------------|-------------------------------|
| Phantom |